Home > Insider Trading > Filing (0000899243-20-024510)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1466301	Clovis Oncology Inc.	CLVS	Pharmaceutical Preparations (2834)	900475355

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1766329	Edward Paul Gross	C/O Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder CO 80301	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-09-03	469	$0.00	26,902	No	4	M	Direct
Common Stock	Disposition	2020-09-03	198	$5.30	26,704	No	4	S	Direct
Common Stock	Acquisiton	2020-09-03	563	$0.00	27,267	No	4	M	Direct
Common Stock	Disposition	2020-09-03	237	$5.30	27,030	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2020-09-03	469	$0.00	469	$0.00
Common Stock	Restricted Stock Units	Disposition	2020-09-03	563	$0.00	563	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
938			No	4	M	Direct
3,375			No	4	M	Direct

Footnotes

Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
On March 27, 2017, the reporting person was granted 7,500 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
On March 1, 2018, the reporting person was granted 9,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.